2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

112. Thalassemia and Globin Gene Regulation: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Biological Therapies, Transfusion, Women’s Health, Biological Processes, Multi-Systemic Interactions, Diseases, Hemoglobinopathies, Thalassemia, Metabolic Disorders, Iron Overload, Research, Clinical Research, Clinical Trials, Epidemiology, Study Population, Human, Adult, Animal Model
PAPER

4655 Clinical and patient-centered implications of reduced transfusion burden with mitapivat in transfusion-dependent thalassemia: A post hoc analysis of ENERGIZE-T

Sujit Sheth, MD, Maria Domenica Cappellini, MD2, Lauren Czapla, APN3, Gavrielle M. Price, PhD4, Hui Shao, PhD5, Vanessa Shih, PharmD6, Antonis Kattamis, MD7, Khaled M Musallam, MD, PhD8
1 Weill Cornell Medicine, New York, New York, United States
2 Fondazione IRCCS Ca' Granda Policlinico Hospital, University of Milan, Milan, Italy
3 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
4 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
5 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
6 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
7 National and Kapodistrian University of Athens, Athens, Greece
8 Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates, Khalifa University, Abu Dhabi, United Arab Emirates, Weill Cornell Medicine, New York, New York, United States

Introduction

For patients (pts) with transfusion-dependent thalassemia (TDT), transfusions are typically needed every 2-5 weeks (wks) and carry a substantial burden for pts, including progressive iron overload that requires chelation therapy, high health care resource utilization, and time spent in health care settings. Mitapivat, a first-in-class oral allosteric activator of pyruvate kinase, including the red blood cell (RBC)-specific PKR and the PKM2 isoforms, is approved to be used in adults with α‑ or β‑thalassemia, regardless of transfusion needs, in the US, EU, Saudi Arabia, and UAE. In ENERGIZE-T (NCT04770779), a phase 3 trial evaluating mitapivat in adults with α- or β-TDT, the primary endpoint was the proportion of pts achieving a transfusion reduction response (TRR), defined as a ≥50% reduction (with a reduction of ≥2 units) in transfused RBCs in any consecutive 12-wk period of the double-blind period (DBP) vs baseline. A significantly greater proportion of pts achieved TRR in the mitapivat arm (52/171 [30.4%]) vs the placebo arm (11/87 [12.6%]; p=0.0003).

Aim

To characterize the onset and duration of TRR among the 52 pts randomized to mitapivat who achieved TRR in the DBP, and to evaluate its clinical implications by estimating reductions in annualized RBC units transfused, transfusional iron intake, and transfusion visit frequency.

Methods

In this post hoc descriptive analysis of the 48-wk ENERGIZE-T DBP, a response period was defined as any 12-wk interval during which a pt achieved TRR. Overlapping or contiguous response periods were combined, and duration of response was defined as the time from the start of the first response period to the end of the last. The time to first response was defined as the time from first dose to the first day of the first response period. The longest duration of response was defined as the duration of the longest continuous response. Cumulative duration of response across all response periods during the DBP is provided. Annualized RBC units transfused and transfusion visit frequency during the DBP were compared with annualized baseline. Impacts on transfusional iron intake per year were calculated assuming 200 mg of iron intake per transfused RBC unit (Cohen et al. Blood 2008).

Results

Among the 52 responders, the median (min, max) time to first response was 0.9 (0.1, 37.1) wks. Mean (standard deviation [SD]) cumulative duration of response during the DBP was 30.9 (14.2) wks. Of the 52 pts, 37 pts (71.2%) experienced a single continuous response (consisting of ≥1 overlapping 12-wk TRR periods), and 15 pts (28.8%) had >1 response period, each lasting a minimum of 12 wks, during the DBP. Taking the longest duration of response for each patient, the mean (SD) duration among all pts was 26.8 (14.5) wks.

At baseline, the 52 responders received a mean (SD) of 27.93 (8.230) annualized RBC units over a mean (SD) of 14.63 (3.310) annualized transfusion visits. During the DBP, responders received a mean (SD) of 10.01 (5.742) fewer RBC units/year, a 38.6% (24.54%) reduction from annualized baseline, corresponding to a mean (SD) reduction in transfusional iron intake of 2002 (1148.5) mg per year. Responders also had a mean (SD) of 3.92 (3.649) fewer transfusion visits per year vs annualized baseline.

Conclusions

Mitapivat responders in ENERGIZE-T experienced rapid reductions in transfusion burden that were sustained over most of the DBP. These analyses show how those reductions translate into additional clinically meaningful benefits—including ~2000 mg less transfusional iron intake and ~4 fewer transfusion visits per year—underscoring the potential of mitapivat to address both the clinical and pt-experienced burdens of transfusion dependence.
Sujit Sheth, MD: Clinical Care Options - Honoraria; BEAM - Honoraria; Bristol Myers Squibb (Celgene) - Honoraria; Plexus - Honoraria; Agios Pharmaceuticals - Honoraria; Physicians' Education Resource - Honoraria; bluebird bio - Honoraria; Bristol Myers Squibb (Celgene) - Research Funding; Regeneron - Research Funding; Pharmacosmos - Research Funding; Agios Pharmaceuticals - Research Funding; Forma - Research Funding; bluebird bio - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); BEAM - Consultancy (Includes expert testimony); Bristol Myers Squibb (Celgene) - Consultancy (Includes expert testimony); Chiesi - Consultancy (Includes expert testimony); Vertex Pharmaceuticals - Consultancy (Includes expert testimony); Fulcrum - Consultancy (Includes expert testimony); CRISPR Therapeutics/Vertex Pharmaceuticals - Membership on a Board/Advisory Committee; Weill Cornell Medicine - Current Employment